A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Conditions:   Solid Tumor, Adult;   Colorectal Cancer;   NSCLC;   Non Small Cell Lung Cancer;   NSCLC, Recurrent;   Non-Small Cell Squamous Lung Cancer;   Pancreas Cancer;   Pancreatic Neoplasm;   Colorectal Adenocarcinoma;   CRC;   Colon Cancer;   Rectal Cancer;   Cancer;   Ovar ian Cancer;   Ovarian Neoplasms;   Mesothelioma;   Mesothelioma, Malignant;   Ovary Cancer;   Lung Cancer;   MESOM Interventions:   Biological: A2B694;   Diagnostic Test: xT CDx with HLA-LOH Assay Sponsors:   A2 Biotherapeutics Inc.;   Tempus Labs Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials